ClinicalTrials.gg
CompletedNCT06371313Updated Apr 17, 2024

Endocrine, Metabolic and Inflammatory Characteristics of Offspring of Mothers With PCOS Hyperandrogenism

An observational study in PCOS, sponsored by Guangdong Women and Children Hospital. Completed at 1 site in China. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-17.

Sponsored by Guangdong Women and Children Hospital · Observational

Study type
Observational
Model
Case-crossover
Time perspective
Cross-sectional
Enrollment
42
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

This study is a cross-sectional study to explore the endocrine metabolism and inflammatory characteristics of the offspring of mothers with PCOS hyperandrogenism, in order to provide a theoretical basis for finding the cause of PCOS.

Read the detailed description

This study randomly selected 20 women with PCOS and hyperandrogenism who gave birth to a singleton at term at Guangdong Maternal and Child Health Hospital from May 2023 to March 2024, and set them as the HA group. In addition, 22 healthy women were randomly selected as controls. group, the fasting blood glucose (FPG) level of the newborn\'s peripheral blood and the androgen, fasting insulin and inflammatory factor levels of the newborn\'s umbilical cord blood were collected respectively.

Among them, the detection indicators of newborn umbilical cord blood include testosterone (T), androstenedione (AND), dehydroepiandrosterone sulfate (DHEA-S), sex hormone binding globulin (SHBG), free androgen index (FAI), Fasting insulin (FINS), white blood cell count (WBC), neutrophil count (NEUT), high-sensitivity C-reactive protein (hs-CRP), and interleukin (IL)-6.

All collected data were statistically analyzed to compare the differences in levels of androgens, fasting insulin, and inflammatory factors in the umbilical cord blood of newborns in the HA group and the control group.

02

Conditions studied

  • PCOS

Browse trials for

Keywords

  • PCOS
  • Hyperandrogenemia
  • Offspring
  • Endocrine and Metabolism
  • Inflammation
03

In context

Inflammation

3,536 studies on the registry are indexed under Inflammation; 642 are open to participants now.

This study's enrollment of 42 is below the median of 100 across 864 observational studies indexed under Inflammation.

Browse Inflammation studies →

Lead sponsor

Guangdong Women and Children Hospital is the lead sponsor of 25 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The women selected into the study group were diagnosed with PCOS before pregnancy and were complicated with hyperandrogenism.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The diagnosis of polycystic ovary syndrome patients must meet the Rotterdam criteria.
  • Aged between 18 and 45 years old.
  • The gestational age of delivery is between 37 and 41 weeks of gestation.
  • Hyperandrogenemia inclusion criteria: elevated peripheral blood androgens, including testosterone, androstenedione, and dehydroepiandrosterone sulfate.
  • Singleton pregnancy.
  • Signed form.

Exclusion criteria

Exclusion Criteria:

  • Combined with reproductive organ malformations or chromosomal abnormalities.
  • Combined with chronic diseases such as diabetes and hypertension.
  • Combined with thyroid disease or other serious systemic diseases such as cardiovascular disease.
  • Multiple pregnancy.
  • Combined with congenital adrenal hyperplasia, Cushing\'s syndrome, hypertension Prolactinoma, and androgen-secreting tumor-related diseases.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-crossover
Time perspective
Cross-sectional
Enrollment
42 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • HA Group

    Maternal hyperandrogenism of PCOS women with full-term singleton delivery were selected, and umbilical cord blood of their newborns was collected.

  • Control Group

    Healthy pregnant women with full-term singleton delivery were randomly selected, and umbilical cord blood of their newborns was collected.

06

What researchers measure

Primary outcomes

  1. Testosterone

    Testosterone is one of the androgens, which can be used to assess androgen levels.

    Time frame: Within one year after neonatal cord blood collection.

  2. Androstenedione

    Androstenedione is one of the androgens, which can be used to assess androgen levels.

    Time frame: Within one year after neonatal cord blood collection.

  3. Dehydroepiandrosterone Sulfate

    Dehydroepiandrosterone Sulfate is one of the androgens, which can be used to assess androgen levels.

    Time frame: Within one year after neonatal cord blood collection.

  4. Sex Hormone Hinding Globulin

    Sex hormone-binding globulin, also known as testosterone-estradiol binding globulin, is a carrier of sex hormones and can reflect the level of sex hormones.

    Time frame: Within one year after neonatal cord blood collection.

  5. Free Androgen Index

    The free androgen index can reflect the biological activity of androgen.

    Time frame: Within one year after neonatal cord blood collection.

  6. Fasting Insulin

    Insulin is a hormone secreted by pancreatic beta cells that lowers blood glucose and produces energy metabolism. Its level can assist in the diagnosis of insulin resistance.

    Time frame: Within one year after neonatal cord blood collection.

  7. White Blood Cell Count

    The white blood cell count can assess the inflammatory status.

    Time frame: Within six hours of neonatal cord blood collection.

  8. Neutrophil Count

    Neutrophil count can be used to assess the inflammatory status.

    Time frame: Within six hours of neonatal cord blood collection.

  9. High-sensitivity C-reactive Protein

    High-sensitivity C-reactive protein can be used to assess the inflammatory status.

    Time frame: Within six hours of neonatal cord blood collection.

  10. Interleukin-6

    Interleukin (IL)-6 can be used to assess the inflammatory status.

    Time frame: Within one year after neonatal cord blood collection.

07

Study locations

1 site
  • Guangdong Women and Children Hosptial
    Guanzhou, Guangdong 511400, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Mar 2024, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2024
First posted
Apr 17, 2024
StartActual
May 1, 2023
Primary completionActual
Mar 5, 2024
CompletionActual
Mar 5, 2024
Last update
Apr 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06371313
Lead sponsor
Guangdong Women and Children Hospital
Responsible party
Li Li (Deputy Director, Institute of Women's and Children's Health, Guangdong Women and Children Hospital) — Principal investigator
First posted
Apr 17, 2024
Start date
May 1, 2023
Primary completion
Mar 5, 2024
Completion
Mar 5, 2024
Last update
Apr 17, 2024

Study contacts

Li Li, M.D.
study chair · Guangdong Women and Children Hospital
Chen Yuan, Master
principal investigator · Guangdong Women and Children Hosptial

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion